Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study by Ayse Oner et al.
RESEARCH Open Access
Subretinal adipose tissue-derived
mesenchymal stem cell implantation in
advanced stage retinitis pigmentosa:
a phase I clinical safety study
Ayse Oner1*, Z. Burcin Gonen2,3, Neslihan Sinim1, Mustafa Cetin2,4 and Yusuf Ozkul2,5
Abstract
Background: This prospective clinical case series aimed to investigate the safety of subretinal adipose tissue-
derived mesenchymal stem cell (ADMSC) implantation in advanced stage retinitis pigmentosa (RP).
Methods: This study included 11 patients with end-stage RP who received subretinal implantation of ADMSCs. All
patients had a total visual field defect and five of them only had light perception. The best corrected visual acuity
(BCVA) in the study was 20/2000. All patients had undetectable electroretinography (ERG). The worst eye of the
patient was operated on and, after total vitrectomy with a 23 gauge, ADMSCs were injected subretinally. Patients
were evaluated at day 1, at weeks 1–4, and then once a month for 6 months, postoperatively. BCVA, anterior
segment and fundus examination, color photography, and optical coherence tomography (OCT) were carried out at
each visit. Fundus fluorescein angiography (FFA), perimetry, and ERG recordings were performed before treatment
and at the end of month 6, and anytime if necessary during the follow-up.
Results: All 11 patients completed the 6-month follow-up. None of them had systemic complications. Five patients
had no ocular complications. One of the patients experienced choroidal neovascular membrane (CNM) at the
implantation site and received an intravitreal anti-vascular endothelial growth factor drug once. Five patients had
epiretinal membrane around the transplantation area and at the periphery, and received a second vitrectomy and
silicon oil injection. There was no statistically significant difference in BCVA and ERG recordings from baseline.
Only one patient experienced an improvement in visual acuity (from 20/2000 to 20/200), visual field, and ERG.
Three patients mentioned that the light and some colors were brighter than before and there was a slight
improvement in BCVA. The remaining seven patients had no BCVA improvement (five of them only had light
perception before surgery).
Conclusions: Stem cell treatment with subretinal implantation of ADMSCs seems to have some ocular complications
and should be applied with caution. The results of this study provide the first evidence of the short-term safety of
ADMSCs in humans, and clarifies the complications of the therapy which would be beneficial for future studies.
To optimize the cell delivery technique and to evaluate the effects of this therapy on visual acuity and the quality of
life of these patients, future studies with a larger number of cases will be necessary.
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Background
Retinitis pigmentosa (RP) is a group of inherited retinal
disorders characterized by progressive loss of photore-
ceptors. The disease initially begins by night blindness,
and progresses to tunnel vision and eventual loss of cen-
tral vision, ending with total blindness. Up to now, there
is no curative treatment for this retinal disease. New ap-
proaches for RP therapy include restoring defective
genes and stem cell transplantation to replace defective
or dead cells [1–5].
Stem cells are undifferentiated cells which have the
ability to self-renew and differentiate into mature cells.
They are highly proliferative, implying that an unlimited
number of mature cells can be generated from a given
stem cell source. On this basis, cell replacement therapy
has been evaluated in recent years as a viable alternative
for various pathologies. This therapy hypothesizes that
new retinal cells could be generated from stem cells to
replace the damaged cells in the diseased retina. This
theory is mainly established from embryonic stem cells
(ESCs) and induced pluripotent stem cells (IPSCs). In
addition, stem cells (particularly mesenchymal stem cells
(MSCs)) are able to perform multiple functions, such as
immunoregulation, anti-apoptosis of neurons, and neu-
rotrophin secreting. MSCs are an adult stem cell popula-
tion of stromal progenitor cells of mesodermal origin
which were originally identified in the bone marrow.
They can also be found in other body systems such as
adipose tissue, liver, umblical cord, central nervous sys-
tem, and dental tissues [2–5]. Many studies suggested
that MSCs are able to maintain and regulate the micro-
environment in different models of retinal degeneration
[6–10]. Experimental studies also reported that MSCs
have the potential to differentiate into retinal progenitor
cells, photoreceptors, and retinal neural-like cells [6, 7].
With the progress in basic medical sciences, several
phase I/II clinical trials were approved by the Food and
Drug Administration (FDA), and recently we have seen
the promising and encouraging results of some of these
stem cell clinical trials [8–13].
In this study, we aimed to investigate the safety of
subretinal adipose tissue-derived mesenchymal stem cell
(ADMSC) implantation in advanced-stage RP.
Methods
This single-center, prospective, phase I clinical safety
study enrolled 11 patients with irreversible vision loss
from RP who were seen in the Retina and Vitreous
Section of the Department of Ophthalmology in our
University. The study was performed in accordance with
the Declaration of Helsinki and was approved by the
Institutional Review Board (Review number for approval:
2014/390). It was also approved by the Review Board of
Stem Cell Applications within the Ministry of Health in
accordance with the regulations in our country (Review
number for approval: 56733164/203). All patients were
instructed about the objectives and methodology of the
study and gave written informed consent to participate.
Patient eligibility
There are limited data about clinical applications of
MSCs and the safety of this therapy still needs to be
clarified. Therefore, the study included patients with
end-stage RP who are considered as legally blind.
Patients were included if they had: 1) a diagnosis of
hereditary retinal dystrophy classified clinically as RP; 2)
an Early Treatment Diabetic Retinopathy Study best cor-
rected visual acuity (BCVA) worse than 20/200; 3) a vis-
ual field less than 20 degrees, considered as legally blind;
4) decreased electroretinography (ERG) recordings; and
5) were aged older than 18 years.
Exclusion criteria were: 1) previous ocular surgery
other than cataract extraction; 2) presence of a cataract
or other media opacity that would prohibit high-quality
ocular imaging or that would affect ERG or visual field
evaluation; 3) presence of other ophthalmic disease, such
as glaucoma, uveitis, strabismus, or nystagmus; 4) any
other systemic disease such as neurological disease that
would affect the results. If both eyes were eligible for
treatment, the eye with the worst visual acuity was used
in the study.
The demographic data of the patients were collected
and ophthalmic evaluations and surgical procedures
were performed by a single retina specialist (AO). Fun-
dus photography, fundus fluorescein angiography (FFA),
optical coherence tomography (OCT), perimetry, and
ERG recordings were performed by the same experi-
enced ophthalmic technician.
All patients had a complete ophthalmic examination
before surgery. BCVA was measured with the Snellen
chart. All patients underwent fundus photography and
FFA using the Zeiss FF 450 (Carl Zeiss Meditec AG,
Germany). OCT was performed using the Heidelberg
OCT Device (Heidelberg Engineering, Heidelberg,
Germany) with a standardized scanning protocol. Visual
field examination was performed by Octopus Goldmann
Perimetry (Octopus 900, Haag Streit İnternational,
Switzerland). ERG tests were recorded with Tomey
Primus 2.5 (Tomey GmbH, Erlangen, Germany) in ac-
cordance with the guidelines of the International Society
for Clinical Electrophysiology of Vision (ISCEV) [14].
Isolation and culture of ADMSCs
To eliminate donor-based differences, ADMSCs ob-
tained from the adipose tissue of a single donor were
used for all patients in this study. Subcutaneous adipose
tissue was carried to the laboratory in a transfer solution
of Dulbecco’s modified Eagle medium (DMEM) with
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1 g/l D-glucose (low glucose; Biological Industries,
Kibbutz Beit Haemek, Israel) containing 2% penicillin-
streptomycin solution (10,000 units/ml penicillin G so-
dium salt, 10 mg/ml streptomycin sulfate; Biological
Industries). Adipose tissue was washed in phosphate-
buffered saline (PBS; Biological Industries) three times
and cut into small pieces and then digested with
2.5 mg/ml collagenase type II (Sigma-Aldrich, Taufkirchen,
Germany) for 30 min at 37 °C to generate single-cell
suspension. The digested tissues were filtered through
a 70-μm cell strainer and centrifuged at 350 g for
5 min to obtain a pellet. The pellet was resuspended
in DMEM-based media containing 10% human serum, 1%
penicillin-streptomycin solution, and 1% stable glutamine
(Biological Industries) and cultured at 37 °C under 5%
CO2. After 3–4 days of maintenance, the culture medium
was removed to eliminate the non-attached cell fraction.
The medium was replaced twice a week. The culture
medium was changed after reaching 80–85% confluence,
and the cells were detached with 0.25% trypsin EDTA so-
lution C (0.05%) and EDTA (0.02%) (Biological Industries).
The cells were collected, centrifuged at 350 g for 5 min,
and expanded to the required duplication. ADMSCs were
then harvested and cryopreserved until use. Before the
appointed surgery date, sufficient cryopreserved vials were
thawed to provide the required dose for administration.
The frozen ADMSCs were thawed and cultured under the
same conditions. ADMSCs were recovered, washed with
PBS and trypsin/EDTA, and then resuspended in saline
solution and transferred to the surgery room in a
temperature-controlled bag within 1 h. The total injection
volume was 2.47 × 106 ± 0.11/150 μl per patient for this
study. The procedure for ADMSC preparation was
performed under good manufacturing practice (GMP)
conditions in the Genome and Stem Cell Center of our
University. All of the donation, manufacturing, and testing
procedures were carried out according to GMP protocols
authorized by the Ministry of Health in our country. For
release testing, ADMSCs were assessed for cell ap-
pearance, viability, identification, purity, content, and
potency. In addition, ADMSCs were screened for
contamination.
For determining the potency, the suppression effect of
MSCs on lymphocytes was studied. A peripheral blood
sample was taken from the healthy donor and peripheral
blood mononuclear cells (PBMCs) were collected by
density gradient centrifugation using lymphocyte separ-
ation medium (LSM; Biological Industries, BI #01-899-
U04). Then PBMCs were incubated at 37 °C in DMEM
culture medium containing 10% human serum, 1% L-glu-
tamine and 1% penicillin-streptomycin. PBMCs were
stimulated with 1% phytohemagglutinin (PHA-P; Sigma,
#L1668) and the effect of MSCs on lymphocyte prolifer-
ation was studied. MSCs (5 × 104) were cultured with
PBMCs (5 × 105) for 48 h, and 0.5 mg/ml MTT was
added. The entire medium was aspirated, and 100 μl
DMSO was added to dissolve formazan crystals after
3 h. Dissolved formazan crystals were read spectro-
photometrically at 570 nm. The percentage inhibition of
lymphocyte proliferation was determined.
Flow cytometry analyses
ADMSCs were subjected to flow cytometry analyses for
confirmation that ADMSCs maintain their phenotypic
characteristics in vitro. After the third passage, cells were
harvested, centrifuged, and resuspended in PBS at a
minimum concentration of 1 × 106 cells/ml. Immunophe-
notyping characterization of ADMSCs was performed
with antibodies against the following combination of hu-
man antigens: CD11b, CD19, CD34, CD44, CD45, CD73,
CD90, and CD105 (BD Stem Flow hMSC kit, BD Cat. No:
562245). Flow cytometry analyses were performed using
Navios (Beckman Coulter, USA) before application to all
patients in this study. The data were analyzed with
KALUZA software (Beckman Coulter).
Subretinal implantation of MSCs
All patients received a routine 23 gauge pars plana vitrec-
tomy operation with retrobulber anesthesia under sterile
conditions. Vitrectomy was carried out using the Dutch
Ophthalmic Research Center EVA (DORC, Zuidland,
Netherlands) system. After core vitrectomy, posterior vitre-
ous detachment was induced with the assistance of triam-
cinolone acetonide and total vitrectomy was completed.
An area called a transition zone (the zone between the af-
fected and relatively unaffected retinal area) far from the
fovea was selected for the subretinal implantation of
ADMSCs. Subretinal ADMSCs were injected at a concen-
tration of 2.47 × 106 ± 0.11/150 μl with a 41-gauge needle.
Fluid-air exchange was performed at the end of surgery.
No laser treatment was performed. All surgery was carried
out under local anesthesia by a single surgeon (AO).
Modified technique
The modified technique focused on the removal of the
whole vitreous gel and the clearance of the scattered
epiretinal stem cells. To shave the peripheral vitreous,
360° scleral indentation was performed cautiously. The
triamcinolone acetonide assistance was repeated to
visualize the residual vitreous fibers, posterior hyaloid
remnants, or preretinal membranes. To decrease the
number of scattered epiretinal stem cells, fluid-air ex-
change was applied at least three times after the subret-
inal implantation procedure.
Postoperative follow-up
Patients were hospitalized at least 1 day after surgery
and they are instructed to maintain a face-down position
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to induce the subretinal spread of MSCs during the first
postoperative day. Ophthalmological evaluations were
performed at day 1, at weeks 1–4, and then once a
month for 6 months after the surgery. BCVA, anterior
segment and fundus examination, color photography,
and OCT were carried out at each visit. FFA, perimetry,
and ERG recordings were performed before surgery and
at the end of month 6, and anytime if necessary during
the follow-up. The patients received topical steroid and
antibiotic eye drops four times a day for 2 months. Low-
dose systemic cyclosporin A (2.5–3 mg/kg/day, twice
daily) was used as an immunosuppressive agent for
2 months starting from 1 week before surgery.
The primary outcome measures were the incidence
and severity of ocular and systemic adverse events asso-
ciated with ADMSC treatment.
Results
Morphology and phenotype of culture-expanded ADMSCs
ADMSCs were spindle-shaped cells with a fibroblast-like
morphology, and they attached to the plate during cell
culture. These cells were found to be efficient according
to the inhibition of lymphocyte proliferation before
release. For immunophenotypic characterization of
ADMSCs, culture-expanded cells at the third passage
were examined for surface protein expression using flow
cytometry. The ADMSCs were positive for CD44, CD73,
CD90, and CD105, and negative for CD11b, CD34,
CD45, and HLA-DR; the results of the analysis are listed
in Table 1 and Fig. 1. No evidence of bacterial or
fungal contamination was observed in the cells which
were tested before release. Cell viability evaluated by
trypan blue exclusion was >90.3 ± 0.5% before cell
transplantation.
Table 2 shows the demographic and clinical features of
the 11 study patients who enrolled in this study. All
completed the 6-month follow-up period. The mean age
of the subjects was 38.2 years (age range 26–57 years).
All subjects had advanced central and peripheral vision
loss in both eyes from RP, which was diagnosed by the
presence of bone spicules on fundus examination and a
flat unrecordable ERG in both eyes. Five of the subjects
had only light perception in both eyes for 5 years or
longer (range 5–10 years).
Follow-up BCVA and eye examination
All 11 patients completed the 6-month follow-up and
none of them had systemic complications. Five patients
had no ocular complications due to the stem cell treat-
ment. One of the patients experienced choroidal neovas-
cular membrane (CNM) at the implant site and received
an intravitreal anti-vascular endothelial growth factor
(VEGF) drug once. The first five patients to be operated
on had epiretinal membrane (ERM) around the implant
area and at the periphery, with localized peripheral trac-
tional retinal detachment at the periphery which re-
quired a second vitrectomy and silicon oil injection
within the second month. This complication is thought
to be due to the vitreal reflux or inadvertent preretinal
injection and unwanted preretinal proliferation of MSCs.
To prevent the occurrence of ERM, the operation tech-
nique was modified as described in the methods section.
This modification inhibited ERM formation in the
remaining six patients.
There was no statistically significant difference in vis-
ual acuity (VA) from baseline. Only one patient experi-
enced VA improvement (from 20/2000 to 20/200).
Three patients mentioned that the light and some colors
were brighter than before and there was a slight im-
provement in VA (See Table 2). The remaining seven
had no VA improvement (five of them only had light
perception before treatment).
Two of the patients experienced a mild vitreus
hemorrhage after surgery which cleared in the first week.
There were no signs of intraocular inflammation in the
study eyes on serial eye examinations. We found no
evidence of adverse proliferation, rejection, or serious
ocular or systemic safety issues related to the implanted
stem cells.
Perimetry
Subject 9 was noted to have improvement in the visual
field on Goldmann perimetry at 1-month follow-up
examination, which appeared sustained at the final 6-
month follow-up visit (Fig. 2). The remaining patients
did not show any improvement regarding the perimetry.
Electroretinography
Ten subjects had flat unrecordable full-field ERG at
baseline and at 6-month follow-up in both eyes. There
was a slight improvement in the ERG recordings of
subject 9 (Fig. 3).
Table 1 Immunophenotype of culture-expanded human
adipose-derived mesenchymal stem cells
Surface markers Positive percentage (%) (n = 11)
CD45 0.5 ± 0.3
CD34 0.5 ± 0.3
CD11b 0.5 ± 0.3
CD19 0.5 ± 0.3
CD105 99.73 ± 0.1
CD73 99.03 ± 0.7
CD90 94.83 ± 0.5
CD44 99.46 ± 0.6
HLA-DR 0.5 ± 0.3
Data are expressed as mean ± standard deviation
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Fluorescein angiography
The FFA of patient 6 showed CNM at month 2 after
treatment (Fig. 4). The remaining ten patients who
underwent ADMSC implantation showed no signs of
fluid collection, edema, or persistent leakage on FFA
(Fig. 5).
OCT Findings
OCT images of five patients demonstrated ERM forma-
tion with distortion of the underlying inner retina, and
varying degrees of retinal edema (Fig. 6). We observed
varying degrees of cell accumulation on the inner
aspects of Bruch’s membrane after surgery on OCT in
all patients, which decreased in size and number during
the follow-up period. All patients showed varying num-
ber of white dots within the retina during the follow-up
period. (Fig. 7)
Discussion
MSCs are characterized by a high proliferation potential
and are able to differentiate into cells of mesodermal,
ectodermal, and endodermal origin. Adipose tissue can
be obtained using simple procedures such as liposuction
performed under local anesthesia, and the number of
MSCs in adipose tissue is relatively large. The isolated
stem cells are easily grown in culture, and they preserve
their properties over many passages. These advantages
make adipose tissue an attractive alternative source of
stem cells [2, 3, 5, 15, 16].
ADMSCs are multipotent and can differentiate into
various cell types, including osteocytes, adipocytes, vas-
cular endothelial cells, cardiomyocytes, pancreatic β-
cells, and hepatocytes [17]. An increasing number of
studies also report that MSCs are capable of giving rise
to neuron-like cells. They are not only able to differenti-
ate into neurons for cell replacement therapy but they
also show paracrine effects by modulating the plasticity
of damaged host tissues. These cells are able to secrete
neurotrophic and survival-promoting growth factors,
Fig. 1 Immunophenotypic characteristics of ADMSCs. Surface marker expressions are represented as percentage expression levels
Table 2 Demographic and visual acuity results according to the







1/44/male/OD LP LP LP
2/57/male/OD LP LP LP
3/42/female/OS LP LP LP
4/34/male/OS 20/20000 20/20000 20/20000
5/34/male/OS 20/2000 20/400 20/2000
6/30/female/OD 20/20000 20/2000 20/2000
7/29/male/OS 20/20000 20/2000 20/2000
8/47/male/OS LP LP LP
9/26/male/OD 20/20000 20/400 20/400
10/46/female/OS LP LP LP
11/32/male/OS 20/20000 20/20000 20/20000
BCVA best corrected visual acuity, LP light perception, RE Right eye, LE Left eye
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restore synaptic transmitter release, integrate into exist-
ing neural and synaptic networks, and re-establish
functional connections [18–21]. In an experimental
ocular hypertension model after intravitreal transplant-
ation, MSCs showed a neuroprotective effect in rats
[20]. These paracrine activities have not been reported
in ESCs or IPSCs. Moreover, MSCs possess strong
immunosuppressive properties and inhibit the release of
pro-inflammatory cytokines [22]. This allows autologous,
as well as allogeneic, transplantation of MSCs. In
addition, there is no reported teratoma formation, and
there are no moral objections or ethical controversies
involved in their application [15, 16]. These advanta-
geous properties lead to the idea of experimental and
clinical applications of MSCs to treat different human
diseases.
Subretinal injection or transplantation of MSCs has
been reported to protect and rescue degenerative retina
in retinal degeneration rat models [6, 23]. An experi-
mental study based on paracrine effects reported that
the cultured rat MSCs could secrete nerve growth factor
(NGF), and that NGF or NGF-neutralizing antibody
could activate Müller cell de-differentiation both in vivo
and in vitro [24]. In another experimental model, several
proteins secreted by human ADMSCs, such as the tissue
inhibitor of metalloproteinase-1 and the secreted protein
acidic and rich in cysteine, have been shown to protect
the retina against light-induced damage in vitro and in
vivo [25]. Another study identified a factor called pro-
granulin as a major secreted protein of ADMSCs which
showed protective effects against retinal damage both in
vitro and in vivo. These findings suggest that ADMSCs
have neuroprotective effects in the light-induced retinal
damage model [26].
Studies have also confirmed that MSCs are capable of
differentiating into different types of retinal cells. A
study by Huang et al. [27] showed that MSCs could dif-
ferentiate into retina pigment epithelium (RPE)-like cells
with similar morphological and phagocytic capabilities
using the photoreceptor outer segments and RPE condi-
tioned medium. In addition, under certain conditions,
MSCs can be further differentiated when transplanted
into damaged retina, thereby replacing damaged retinal
cells [27, 28]. The early signs of MSC differentiation into
retinal progenitor cells were observed at 24 h of co-
culture, and the early differentiated retinal lineage cells
appeared at 72 h (neurons, rods, Müller cells, retinal
ganglion cells, and retinal pigmented epithelial cells).
These changes increased during further culture [29]. An-
other study including in vitro culture and expansion of
bone marrow-derived MSCs in rats (rMSCs) showed
that rMSCs could differentiate into retinal neural-like
cells [30]. In an experimental study by Castanheira et al.
[31] MSCs were injected into the vitreous cavity of laser
damaged retina. After 8 weeks, they found that the ma-
jority of MSCs migrated to the ganglion cell layer, the
inner nuclear layer, and the outer nuclear layer, and
these migrated cells expressed markers of photoreceptor
cells, bipolar cells, amacrine cells, and Müller glial cells
[31]. In a recent experimental study by Li et al. [32],
subretinal transplantation of human ADMSCs into rats
significantly improved the visual function 2 weeks after
the transplantation, and this therapeutic effect persisted
up to 8 weeks after treatment. They concluded that this
therapy effectively delayed the retinal degeneration,
enhanced the retinal cell survival, and improved the visual
Fig. 2 Perimetry results for subject 9 before treatment (a) and after
treatment (b). Note the improvement in visual field
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function, and that this was mainly due to ADMSC-
dependent anti-apoptotic and neuroprotective effects
through its secretion of growth and neurotrophic factors
including VEGF [32]. The survival of human ADMSCs for
a period of 90 days in the rat vitreous humor and an even
longer period of up to 6 months in other eye tissues makes
them a promising source to be considered in the regenera-
tive treatment of eye diseases [33].
The eye has numerous advantages for developing
stem cell therapies as all tissues of the eye are
Fig. 3 ERG results of subject 9. Rod, maximal combined, and flicker responses before treatment (a) and after treatment (b). Before treatment, all
of the waves were flat; there was a slight improvement in ERG recordings after treatment
Fig. 4 FFA results for patient 6. Color fundus showing hemorrhage and CNM (a), FFA images including early (b) and late (c) phases showing an
increase in hyperfluorescence, and OCT image showing elevation and intraretinal fluid (d) due to CNM
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surgically accessible, and transplanted cells can be
monitored. Moreover, the ocular immune privilege
might greatly simplify immunosuppressive treatment
after transplantation.
After the encouraging results of experimental studies,
clinical trials of stem cell transplantation have begun
recently in the USA and Europe. In 2012, Schwartz et
al. [11] reported preliminary safety data of human
ESCs on one dry age-related macular degeneration
(AMD) patient and one Stargardt macular dystrophy
(SMD) patient. The subretinal transplanted human
ESC-derived RPE cells showed no signs of hyper-
proliferation, tumorigenicity, ectopic tissue formation,
or apparent rejection after 4 months. The 22-month
follow-up data of this study included nine dry AMD
and nine SMD patients. BCVA improved in ten eyes,
improved or remained the same in seven eyes, and
decreased by more than ten letters in one eye,
whereas the untreated fellow eyes of the patients did
not show similar improvements in VA. The results of
this study provide the first evidence of the medium-
term to long-term safety, graft survival, and possible
biological activity of pluripotent stem cells in individ-
uals with retinal disease [12].
In another clinical study with human ESC-derived
RPE cells [13], the authors reported the safety and
tolerability of subretinal transplantation in four Asian
patients: two with dry AMD and two with SMD. The
patients were followed for 1 year and there was no
evidence of adverse proliferation, tumorigenicity, ectopic
tissue formation, or other serious safety issues related to
the transplanted cells. Visual acuity improved 9–19 let-
ters in three patients and remained stable in one patient.
These results confirmed that human ESC-derived cells
Fig. 5 FFA results for patient 7. Baseline color fundus (a), early phase (b) and late phase (c) FFA photos of subject 7, and 6-month color fundus
(d), early phase (e) and late phase (f) FFA photos of the same patient. There was staining due to the subretinal scar tissue in the implantation area
in the late phase angiogram (black arrow)
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Fig. 6 OCT images of five patients (a–e) demonstrated ERM formation with distortion of the underlying inner retina and varying degrees of
retinal edema. There were also varying degrees of cell accumulation on the inner aspects of Bruch’s membrane
Fig. 7 OCT images of subject 9 at month 1 (a) and month 6 (b). Note the decreasing number of hyper-reflective dots within the retina
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could serve as a potentially safe new source for regen-
erative medicine [13].
In a prospective, phase I study, including three pa-
tients with RP and two patients with cone-rod dys-
trophy, Siqueira et al. [8] evaluated the short-term safety
of a single intravitreal injection of autologous bone
marrow-derived MSCs and they reported no detectable
structural or functional toxicity to the retina over a
period of 10 months. They measured a one-line im-
provement in BCVA in four patients 1 week after injec-
tion, and this improvement was maintained throughout
follow-up [8]. The follow-up data of this study included
20 patients with RP who received intravitreal bone
marrow-derived MSCs. They evaluated the vision-
related quality of life of patients using the National Eye
Institute Visual Function Questionnaire-25 (NEI VFQ-
25) before treatment and 3 and 12 months after treat-
ment. There was a statistically significant improvement
in the quality of life of patients 3 months after treat-
ment, whereas by month 12 there was no statistically
significant difference from baseline [9].
In a recent study by Park et al. [10], six subjects (six
eyes) with irreversible vision loss from retinal vascular
occlusion, hereditary or non-exudative AMD, or RP re-
ceived a mean of 3.4 million intravitreal bone marrow-
derived MSCs. The therapy was well tolerated with no
intraocular inflammation or hyperproliferation; BCVA
and full-field ERG showed no worsening after 6 months,
and they concluded that intravitreal autologous bone
marrow-derived MSC cell therapy appeared feasible.
To the best of our knowledge, ours is the first clinical
study including the results of subretinal implantation of
ADMSCs in RP patients. The purpose of this study was
to determine the safety and tolerability of this therapy.
We found no serious systemic or ocular adverse events
in these 11 subjects. Ophthalmological examinations,
including visual acuity, perimetry, color fundus photog-
raphy, FFA, OCT, and ERG, did not identify any signifi-
cant safety concerns after surgery.
The first five patients to be operated on developed
ERMs and localized peripheral tractional retinal detach-
ments which required a second surgery. This is relatively
high compared with the rate of ERM development after
the vitrectomy procedure. We thought that this compli-
cation may have arisen from inadvertent preretinal
injection of cells or reflux of transplanted cells from the
subretinal space. With the idea that rinsing the epiretinal
area may help to decrease the number of scattered
epiretinal stem cells, the technique was modified and
fluid-air exchange was applied at least three times after
the subretinal implantation procedure.
Vitreous abnormalities have been well documented
in all RP stages. In the advanced stage of the disease,
an atypical posterior vitreous detachment, posterior
vitreoschisis, and formation of condensed irregular
fiber aggregates could be found in RP patients [34–36].
These abnormalities could cause some difficulties in the
removal of posterior vitreous which may lead to the ERM
formation found in our study. In our modified technique,
we paid extreme attention to shave the peripheral vitre-
ous, and to visualize the residual posterior vitreous, pos-
terior hyaloid remnants, or preretinal membranes and
remove them. This modification prevented the develop-
ment of ERM in the remaining six patients.
ERM formation was also reported in the study by Song
et al. in two of the four patients who received subretinal
human ESC-derived RPE cells [13]. They reported that
ERM developed at 2 weeks in both patients and caused
minimal distortion of the underlying inner retina which
did not require a second surgery [13].
During the follow-up period, CNM developed in one
of our study patients in the MSC transplanted eye at
8 weeks which was successfully treated with anti-VEGF
drugs. The location of the CNM was primarily in the
bleb area. Song et al. [13] also reported a CNM forma-
tion in one of four patients who received three monthly
Lucentis injections. This complication may have devel-
oped due to trauma to the Bruch’s membrane during the
surgical procedure. Another possible explanation for this
complication may be the angiogenic properties of MSCs.
There is experimental evidence that ADMSCs promote
de novo formation of vascular structures and that these
cells also secrete growth factors such as VEGF-A, VEGF-
B, HIF-1α, and glial-derived neurotrophic factor (GDNF)
under hypoxic conditions which could lead to endothe-
lial cell network formation and trigger active neovascular
growth [37–39].
Immunosuppression is still controversial and there is
no established standard immunosuppressive therapy
protocol after stem cell therapy. Among cell injection
sites, the subretinal space is particularly advantageous as
it is maintained as an immune privileged site by the con-
nections between the RPE layer. Some authors believe
that if the blood-retinal barrier is preserved during sur-
gery, immunosuppressive drugs are not necessary. Thus,
the success of subretinal transplantation depends on
maintenance of RPE integrity. Moreover, both ESCs and
MSCs have negligible immunogenicity, reducing the
chance of rejection [40, 41]. On the other hand, some
authors believe that there may be a disruption of the
blood-retinal barrier by subretinal injection; the balance
of the subretinal microenvironment may be broken and
immunosuppression will be necessary until recovery of
the barrier. There is also some evidence that suppression
of the recipient’s immune response will increase the sur-
vival rate of transplanted cells [41]. Cyclosporin A is one
of the most frequently used immunosuppressive drugs in
ophthalmology. An animal study in retinal degenerative
Oner et al. Stem Cell Research & Therapy  (2016) 7:178 Page 10 of 12
mice showed that cyclosporin A enhanced the survival of
transplanted subretinal human retinal progenitor cells
[42]. We preferred short-term cyclosporin A treatment for
immunosuppression in our study. Further investigation is
needed regarding immunosuppressive therapy in stem cell
transplantation.
These are the limitations to our study. We know that
the study population is small. Furthermore, the study
included patients with poor visual function who are
considered as legally blind which hindered our ability to
perform reliable measurements of visual functions. Only
one patient had an improvement in visual acuity (from
20/2000 to 20/400), perimetry, and ERG. Three patients
mentioned that the light and some colors were brighter
than before and there was a slight improvement in VA.
The remaining seven patients had no VA improvement;
six of them were only perception-positive before surgery.
Visual field examinations were unreliable because of
poor fixation and high false-negatives in nearly all of the
participants. Patients with better VA are needed to
determine the effect of this therapy on VA and the visual
field. We observed small deposits on the inner aspects
of Bruch’s membrane after surgery on OCT during the
follow-up period. However, we do not know if these
deposits are markers of donor cells, since ingestion of
donor stem cells by host macrophages may produce a
similar ophthalmoscopic appearance.
Conclusion
Stem cell treatment with subretinal implantation of
ADMSCs seems to have some ocular complications and
should be applied with caution. The results of this study
provide the first evidence of the short-term safety of
subretinal implantation of ADMSCs in humans and
clarifies the complications of the therapy which would
be beneficial for future studies. To optimize the cell
delivery technique and to evaluate the effects of this
therapy on visual acuity and the quality of life of these
patients, future studies including larger number of cases
with better visual acuities will be necessary.
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